Browse > Article
http://dx.doi.org/10.19125/jmrd.2017.3.1.20

Keratanase II Digestion Accompanied with a Liquid Chromatography/Tandem Mass Spectrometry for Urinary Keratan Sulfate Quantitative Analysis  

Chuang, Chih-Kuang (Division of Genetics and Metabolism, Department of Medical Research, Mackay Memorial Hospital)
Lin, Hsiang-Yu (Division of Genetics and Metabolism, Department of Medical Research, Mackay Memorial Hospital)
Wang, Tuen-Jen (Department of Laboratory Medicine, Mackay Memorial Hospital)
Huang, Sung-Fa (Department of Laboratory Medicine, Mackay Memorial Hospital)
Lin, Shuan-Pei (Division of Genetics and Metabolism, Department of Medical Research, Mackay Memorial Hospital)
Publication Information
Journal of mucopolysaccharidosis and rare diseases / v.3, no.1, 2017 , pp. 20-27 More about this Journal
Abstract
Purpose: Mucopolysaccharidosis IV (MPS IV) is a disease characterized by deficient activity of N-acetylgalactosamine-6-sulfatase (GALNS) causing excessive lysosomal storage of keratan sulfate (KS). The identification of the relevant disaccharide units of KS after keratanase II digestion followed by liquid chromatography/tandem mass spectrometry detection (LC-MS/MS) is validated and applicable for the preliminary diagnosis of MPS IV. Methods: A total of 67 urine samples were collected and analyzed from 11 MPS IV patients comprising 10 MPS IVA and one MPS IVB patients, and 56 normal controls. Urinary glycosaminoglycan was first precipitated by the Alcian blue method followed by a digestion of keratanase II. The protonated species of the digested disaccharide products were detected by using multiple reaction monitoring experiment. Results: One particular disaccharide of KS was selected. The transition mass-to-charge (m/z) of the parent ion and its daughter ion after collision was $462.0{\rightarrow}97.0$, whereas the chondrosine used as an internal standard in this assay was m/z $353.9{\rightarrow}73.0$. The results corresponded well with the two-dimensional electrophoresis method. The quantities of urinary KS were significantly raised in confirmed MPS IV patients when comparing with those of normal controls ($170.2{\pm}81.1$ vs. $4.06{\pm}1.92{\mu}g/mL$). Conclusion: The LC-MS/MS method for MPS IVA determination is specific, sensitive, validated, and applicable for urinary KS quantification. This method can be used not only as a first-line biochemistry examination of MPS IVA, but also as an outcome survey after enzyme replacement therapy.
Keywords
Mucopolysaccharidosis IV; Keratan sulfate (KS); Keratanase; Liquid chromatography/tandem mass spectrometry (LC-MS/MS); Two-dimensional electrophoresis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Champe PC, Harvey RA. Glycosaminoglycans in Biochemistry: Lippincott's Illustrated Reviews, 2nd ed. Philadelphia: J.B. Lippincott Company, 1994.
2 van Diggelen OP, Zhao H, Kleijer WJ, Janse HC, Poorthuis BJ, van Pelt J, et al. A fluorimetric enzyme assay for the diagnosis of Morquio disease type A (MPS IV A). Clin Chim Acta 1990;187:131-9.   DOI
3 Wood TC, Harvey K, Beck M, Burin MG, Chien YH, Church HJ, et al. Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis 2013;36:293-307.   DOI
4 Funderburgh JL. Keratan sulfate: structure, biosynthesis, and function. Glycobiology 2000;10:951-8.   DOI
5 Funderburgh JL. Keratan sulfate biosynthesis. IUBMB Life 2002;54:187-94.   DOI
6 Meyer K, Hoffman P, Linker A. Mucopolysaccharides of costal cartilage. Science 1958;128:896.
7 Oguma T, Tomatsu S, Okazaki O. Analytical method for determination of disaccharides derived from keratan sulfates in human serum and plasma by high-performance liquid chromatography/turbo-ionspray ionization tandem mass spectrometry. Biomed Chromatogr 2007;21:356-62.   DOI
8 Martell LA, Cunico RL, Ohh J, Fulkerson W, Furneaux R, Foehr ED. Validation of an LC-MS/MS assay for detecting relevant disaccharides from keratan sulfate as a biomarker for Morquio A syndrome. Bioanalysis 2011;3:1855-66.   DOI
9 Khaliq T, Sadilek M, Scott CR, Turecek F, Gelb MH. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis IVA. Clin Chem 2011;57:128-31.   DOI
10 de Ru MH, van der Tol L, van Vlies N, Bigger BW, Hollak CE, Ijlst L, et al. Plasma and urinary levels of dermatan sulfate and heparin sulfate derived disaccharides after longterm enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans. J Inherit Metab Dis 2013;36:247-55.   DOI
11 Khan S, Almeciga-Diaz CJ, Sawamoto K, Mackenzie WG, Theroux MC, Pizarro C, et al. Mucopolysaccharidosis IVA and glycosaminoglycans. Mol Genet Metab 2017;120:78-95.   DOI
12 Sawamoto K, Suzuki Y, Mackenzie WG, Theroux MC, Pizarro C, Yabe H, et al. Current therapies for Morquio A syndrome and their clinical outcomes. Expert Opin Orphan Drugs 2016;4:941-51.   DOI
13 Tomatsu S, Azario I, Sawamoto K, Pievani AS, Biondi A, Serafini M. Neonatal cellular and gene therapies for mucopolysaccharidoses: the earlier the better? J Inherit Metab Dis 2016;39:189-202.   DOI
14 Tomatsu S, Sawamoto K, Shimada T, Bober MB, Kubaski F, Yasuda E, et al. Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations. Expert Opin Orphan Drugs 2015;3:1279-90.   DOI
15 Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: The Metabolic and Molecular Bases of Inherited Disease. 8th ed. Scriver CR, Beaudet AL, Valle D, et al, editors. New York: McGraw-Hill Book Company, 2001:3421-52.
16 Tomatsu S, Yasuda E, Patel P, Ruhnke K, Shimada T, Mackenzie WG, et al. Morquio A syndrome: diagnosis and current and future therapies. Pediatr Endocrinol Rev 2014;12:141-51.
17 Tomatsu S, Fukuda S, Masue M, Sukegawa K, Fukao T, Yamagishi A, et al. Morquio disease: isolation, characterization and expression of full-length cDNA for human Nacetylgalactosamine-6-sulfate sulfatase. Biochem Biophys Res Commun 1991;181:677-83.   DOI
18 Baker E, Guo XH, Orsborn AM, Sutherland GR, Callen DF, Hopwood JJ, et al. The Morquio A syndrome (mucopolysaccharidosis IVA) gene maps to 16q24.3. Am J Hum Genet 1993;52:96-8.
19 Tomatsu S, Nishioka T, Montano AM, Gutierrez MA, Pena OS, Orii KO, et al. Mucopolysaccharidosis IVA: identification of mutations and methylation study in GALNS gene. J Med Genet 2004;41:e98.   DOI
20 Morrone A, Caciotti A, Atwood R, Davidson K, Du C, Francis-Lyon P, et al. Morquio A syndrome-associated mutations: a review of alterations in the GALNS gene and a new locusspecific database. Hum Mutat 2014;35:1271-9.
21 Tomatsu S, Montano AM, Oikawa H, Smith M, Barrera L, Chinen Y, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Cur Pharm Biotech 2011;12:931-45.   DOI
22 Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet 1997;101:355-8.   DOI
23 Lin HY, Chuang CK, Chen MR, Chiu PC, Ke YY, Niu DM, et al. Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA. Orphanet J Rare Dis 2014;9:21.   DOI
24 Lin HY, Shih SC, Chuang CK, Lee K, Chen M, Lin HC, et al. Assessment of hearing loss by pure-tone audiometry in patients with mucopolysaccharidoses. doi: 10.1016/j.ymgme.2014.02.003.   DOI
25 Lowry RB, Applegarth DA, Toone JR, MacDonald E, Thunem NY. An update on the frequency of mucopolysaccharide syndromes in British Columbia. Hum Genet 1990;85:389-90.
26 Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatria 2000;105(e10):1-6.   DOI
27 Hopwood JJ, Harrison JR. High-resolution electrophoresis of urinary glycosaminoglycans: an improved screening test for the mucopolysaccharidoses. Anal Biochem 1982;119: 120-7.   DOI
28 Nelson J, Crowhurst J, Carey B, Greed L. Incidence of the mucopolysaccharidoses in Western Australia. Am J Med Genet A 2003;123:310-3.
29 Lin HY, Lin SP, Chuang CK, Niu DM, Chen MR, Tsai FJ, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am J Med Genet A 2009;149A:960-4.   DOI
30 Chuang CK, Lin SP, Chung SF. Diagnostic screening for mucopolysaccharidoses by the dimethylmethylene blue method and two dimensional electrophoresis. Chin Med (Taipei) 2001;64:15-22.
31 Dembure PP, Roesel RA. Screening for mucopolysaccharidoses by analysis of urinary glycosaminoglycans. In: Hommes FA, editor. Techniques in Diagnostic Human Biochemical Genetics - A Laboratory Manual. New York: Wiley-Liss, Inc., 1991:77-86.